NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: JUBLPHARMA · data 2026-10-31
Jubilant Pharmova Limited
In plain words
Price: 21.9% below its 52-week high of ₹1,183.
Delivery: 44.6% of traded shares were kept for delivery over the last 10 sessions, against 48.9% over the last 60.
Latest results: a net profit of ₹57 cr for the quarter ended Jun 2026 (-45.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹8,608 cr |
| Net profit (last 12 months) | ₹352 cr |
| Sales growth, 3 years (yearly) | 9.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 47.7% (unchanged in a year), pledged 6.6%, institutions 28.4%.
P/E 41.6, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.0%, ROCE 6.5%, operating margin 8.7%: how much profit it earns on the money it uses.
Debt/equity 0.51, Profit growth — and sales growth 9.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (6.0%).
- Promoters have pledged 6.6% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
JUBLPHARMA Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,229.4 crore, up 17.3% YoY and down 2.6% QoQ.
Net profit was ₹56.5 crore, down 45.1% YoY and down 52.7% QoQ.
Operating margin was 11.1% (15.2% a year ago).
EPS was ₹3.57, down 45% YoY and down 52.7% QoQ.
JUBLPHARMA के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,229.4 करोड़; पिछले साल की तुलना में 17.3% की बढ़त, पिछली तिमाही की तुलना में 2.6% की गिरावट।
शुद्ध मुनाफ़ा: ₹56.5 करोड़; पिछले साल की तुलना में 45.1% की गिरावट, पिछली तिमाही की तुलना में 52.7% की गिरावट।
ऑपरेटिंग मार्जिन: 11.1% (एक साल पहले 15.2%)।
EPS: ₹3.57; पिछले साल की तुलना में 45% की गिरावट, पिछली तिमाही की तुलना में 52.7% की गिरावट।
JUBLPHARMAના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,229.4 કરોડ; ગયા વર્ષની સરખામણીએ 17.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 2.6% ઘટાડો.
ચોખ્ખો નફો: ₹56.5 કરોડ; ગયા વર્ષની સરખામણીએ 45.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 52.7% ઘટાડો.
ઓપરેટિંગ માર્જિન: 11.1% (એક વર્ષ પહેલાં 15.2%).
EPS: ₹3.57; ગયા વર્ષની સરખામણીએ 45% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 52.7% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
13/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 8/30: Delivery 52.6% over the last 20 sessions vs 46.7% in the 40 before (1.13x); shares delivered per day 0.77x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Results ● Dividend
- 12 Oct 26Deal Block deal: ABAKKUS FOUR2EIGHT OPPORTUNITIES FU… bought ₹100.65 cr (net ₹0 cr) +1.1% next session
- 10 Aug 26Results Q1 FY27 results: profit −45.1% YoY +3.5% next session
- 24 Jul 26Dividend Dividend ₹5 (ex-date) +0.9% next session
- 22 May 26Results Q4 FY26 results: profit −22.3% YoY -0.4% next session
- 6 Feb 26Results Q3 FY26 results: profit −44.6% YoY -3.2% next session
- 31 Oct 25Results Q2 FY26 results: profit +17.0% YoY +4.6% next session
- 29 Jul 25Results Q1 FY26 results: profit −78.7% YoY +5.3% next session
- 25 Jul 25Dividend Dividend ₹5 (ex-date) -0.1% next session
- 16 May 25Results Q4 FY25 results: turned to profit vs a year ago +6.0% next session
- 31 Jan 25Results Q3 FY25 results: profit +51.0% YoY +2.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹2,229 cr | ₹57 cr | -45.1% | 11.1% | 3.57 |
| Mar 2026 | ₹2,290 cr | ₹119 cr | -22.3% | 14.8% | 7.55 |
| Dec 2025 | ₹2,123 cr | ₹56 cr | -44.6% | 13.6% | 3.52 |
| Sept 2025 | ₹1,966 cr | ₹120 cr | +17.0% | 17.4% | 7.59 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 47.68% | 47.68% | 47.68% | 47.68% |
| Foreign institutions (FII) | 15.38% | 15.87% | 15.90% | 15.96% |
| Domestic institutions (DII) | 13.02% | 12.40% | 11.62% | 11.22% |
| Mutual funds | 9.42% | 8.99% | 8.03% | 7.69% |
| Retail investors | 10.60% | 10.73% | 11.14% | 11.42% |
| Number of shareholders | 82,602 | 82,703 | 86,347 | 90,133 |
Common questions
What was Jubilant Pharmova Limited's latest quarterly profit?
Jubilant Pharmova Limited reported a net profit of ₹57 cr for the quarter ended Jun 2026 (-45.1% on the same quarter a year earlier), on revenue of ₹2,229 cr.
How much do promoters hold in Jubilant Pharmova Limited?
Promoters held 47.68% of Jubilant Pharmova Limited at the end of Sept 2026, with 6.58% of promoter shares pledged.
Is Jubilant Pharmova Limited debt-free?
Its latest reported debt-to-equity ratio is 0.51.
What is Jubilant Pharmova Limited's P/E ratio?
About 41.7, based on the last 12 months' earnings and a price of ₹923.8 (data 2026-10-31).
What is the 52-week high and low of Jubilant Pharmova Limited?
The 52-week high is ₹1,183 and the 52-week low is ₹786.05.
Mutual funds holding Jubilant Pharmova Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹69 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.84% | ₹51 cr |
| An open ended fund for investment for children having a lock-in for at least 5 years or till the child attains age of majority | Aditya Birla Sun Life Mutual Fund | 0.90% | ₹11 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 0.60% | ₹7 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Jubilant Pharmova Limited | ₹923.8 | ₹14,729 cr | 41.7 | — | 6% | 6.5% | 0.51 | -19.6% |
| AstraZeneca Pharma India Limited | ₹6,364.5 | ₹15,918 cr | 93.8 | — | 23.9% | 25.5% | 0.13 | -31.8% |
| Alembic Pharmaceuticals Limited | ₹797.85 | ₹15,682 cr | 22.6 | — | 12.3% | 11.8% | 0.25 | -11.4% |
| NATCO Pharma Limited | ₹782.4 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -4.8% |
| Indegene Limited | ₹586.8 | ₹14,161 cr | 34.5 | 4.2 | 13.9% | 15.9% | 0.05 | +7.5% |
| Marksans Pharma Limited | ₹306.2 | ₹13,896 cr | 26.9 | — | 15.2% | 16.3% | 0.11 | +66.7% |
Compare JUBLPHARMA with ASTRAZEN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open JUBLPHARMA in NSE Scanner →